Interferon-based therapies in COVID-19.
作者信息
Kow Chia Siang, Hasan Syed Shahzad
机构信息
School of Postgraduate Studies, International Medical University, Kuala Lumpur, Malaysia.
School of Applied Sciences, University of Huddersfield, Huddersfield, United Kingdom; School of Biomedical Sciences & Pharmacy, University of Newcastle, Callaghan, Australia.
出版信息
Int Immunopharmacol. 2021 Apr;93:107415. doi: 10.1016/j.intimp.2021.107415. Epub 2021 Jan 28.
Abstract
摘要
相似文献
1
Interferon-based therapies in COVID-19.COVID-19中基于干扰素的疗法。
Int Immunopharmacol. 2021 Apr;93:107415. doi: 10.1016/j.intimp.2021.107415. Epub 2021 Jan 28.
2
Obesity and its nurturing effect on hepatitis C.
Hepatology. 2003 Sep;38(3):557-9. doi: 10.1053/jhep.2003.50413.
3
Advances in therapy for chronic hepatitis C.慢性丙型肝炎治疗进展
Clin Liver Dis. 2001 Nov;5(4):1009-23. doi: 10.1016/s1089-3261(05)70206-3.
4
Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations.基于干扰素的联合疗法对 COVID-19 危重症患者的抗病毒活性：初步观察
J Glob Antimicrob Resist. 2021 Mar;24:124-126. doi: 10.1016/j.jgar.2020.12.011. Epub 2020 Dec 29.
5
Interferon therapy.干扰素疗法。
Can J Gastroenterol. 1997 Oct;11(7):563-4.
6
Advances in therapy for hepatitis C infection.丙型肝炎感染治疗的进展。
Microbes Infect. 2002 Oct;4(12):1237-46. doi: 10.1016/s1286-4579(02)01651-9.
7
Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon.
J Hepatol. 2003;39 Suppl 1:S164-7. doi: 10.1016/s0168-8278(03)00329-5.
8
Interferon therapy for hepatitis C.丙型肝炎的干扰素治疗。
Lancet. 1996 Oct 12;348(9033):973-4. doi: 10.1016/S0140-6736(05)64920-3.
9
[HIV-naive patients speak for pegylated interferon].[初治HIV患者对聚乙二醇化干扰素的看法]
Hautarzt. 2003 Jun;54(6):517.
10
Novel interferons for treatment of hepatitis C virus.用于治疗丙型肝炎病毒的新型干扰素。
Clin Liver Dis. 2009 Aug;13(3):351-63. doi: 10.1016/j.cld.2009.05.004.
引用本文的文献
1
Analysis of the Differential Expression and Antiviral Activity of Porcine Interferon-α In Vitro.猪α干扰素体外差异表达及抗病毒活性分析
Int J Pept Res Ther. 2023;29(3):42. doi: 10.1007/s10989-023-10508-3. Epub 2023 Apr 8.
2
Pathogenesis and treatment of cytokine storm in COVID-19.新型冠状病毒肺炎细胞因子风暴的发病机制与治疗
Turk J Biol. 2021 Aug 30;45(4):372-389. doi: 10.3906/biy-2105-37. eCollection 2021.
3
Commentary: Why Haven't We Found an Effective Treatment for COVID-19?评论：为何我们尚未找到针对新冠病毒病的有效治疗方法？
Front Immunol. 2021 Jul 5;12:714175. doi: 10.3389/fimmu.2021.714175. eCollection 2021.
本文引用的文献
1
Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.联合使用 IFNβ1 和洛匹那韦/利托那韦治疗，可增加严重 COVID-19 感染住院患者的氧合、存活率和出院率。
Int Immunopharmacol. 2021 Mar;92:107329. doi: 10.1016/j.intimp.2020.107329. Epub 2020 Dec 26.
2
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
3
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.吸入用干扰素 β-1a（SNG001）治疗 SARS-CoV-2 感染的安全性和有效性：一项随机、双盲、安慰剂对照、2 期临床试验。
Lancet Respir Med. 2021 Feb;9(2):196-206. doi: 10.1016/S2213-2600(20)30511-7. Epub 2020 Nov 12.
4
Autoantibodies against type I IFNs in patients with life-threatening COVID-19.COVID-19 危重症患者体内针对 I 型干扰素的自身抗体。
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4585. Epub 2020 Sep 24.
5
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.COVID-19 危重症患者的 I 型 IFN 免疫先天缺陷。
Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4570. Epub 2020 Sep 24.
Zotero 插件